Arjun picked up his phone and called the rep. “Rajesh, Dr. Iyengar—did she prescribe Nebuflam-D in week one?”
And yet, week four of the launch, the MIS dashboard showed a flat green line where a hockey stick should have been. Fdc Sales Mis
A pause. “Sir, she said the combination gave some patients palpitations. She switched to separate molecules.” Arjun picked up his phone and called the rep
“And week three?”
But who? A rep desperate to meet target? A stockist colluding with a retailer? Or the MIS itself—not the software, but the people who controlled what data entered it. A pause
Palpitations. The steroid component had a known but rare cardiac risk. In clinical trials, it occurred in 0.3% of patients. But if even one patient reported it to a senior doctor like Iyengar, she would blacklist the FDC forever. The MIS, however, would not capture why she stopped. It would only show a line descending. Numbers without stories were dangerous.
Outside, the city was asleep. But somewhere, a patient with chronic bronchitis was breathing shallowly, having bought only half a course of the expectorant, leaving the steroid untouched—because a chemist had whispered, “Don’t take this combo, beta. Too risky.”